Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26973212 | 0.81 | TDP1 (0.30) | — | |
| SCHEMBL23291660 | 0.73 | MAPT (0.42) | KMT2A | |
| SCHEMBL30434181 | 0.65 | CYP2A6 (0.40) | — | |
| SCHEMBL30973442 | 0.65 | TDP1 (0.30) | — | |
| SCHEMBL9780107 | 0.63 | GPR3 (0.46) | KMT2A | |
| SCHEMBL17703504 | 0.60 | — | — | |
| SCHEMBL7709627 | 0.60 | — | — | |
| SCHEMBL31309382 | 0.60 | — | — | |
| SCHEMBL24446064 | 0.60 | CYP1A2 (0.34) | KMT2A | |
| SCHEMBL28899958 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | HTT, HYPK, FH | KMT2A 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.